Structure-based development of novel adenylyl cyclase inhibitors

Journal of Medicinal Chemistry

Volumn 51, Issue 15, 2008, Pages 4456-4464

  Schlicker, Christine ^a   Rauch, Annika ^a   Hess, Ken C ^b   Kachholz, Barbara ^a   Levin, Lonny R ^b   Buck, Jochen ^b   Steegborn, Clemens ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [BROMO (1 NAPHTHYL)METHYL]NAPHTHALENE; 1,2,3,4,5,6,7,8,13,13,14,14 DODECACHLORO 1,4,4A,5,8,8A,12B OCTAHYDRO 11 SULFO 1,4:5,8 DIMETHANOTRIPHENYLENE 10 CARBOXYLIC ACID; 17,24 DIHYDROXY 10 (4 METHOXYBENZYL) 4,7,9,13,15,29 HEXAMETHYL 22 OXA 3,6,9,12,15,29 HEXAAZATETRACYCLO[14.12.2.2 18,21 .1 2 3,27]TRITRIACONTA 18,20,23(31),24,26,32 HEXAENE 2,5,8,11,14,30 HEXONE; 2 BROMO 1 (9 BROMO 3 PHENANTHRYL) 1 PROPANONE; 2,3 BROMO 1 [4 [HYDROXY(OXIDO)AMINO]PHENYL] 3 (4 QUINOLINYL) 1 PROPANONE; 2,3,6,23 TETRAHYDROXYURS 12 EN 28 OIC ACID; 3,20 DIOXOPREGN 4 EN 21 YL 4 BROMOBENZENESULFONATE; 4 (DIMETHYLAMINO) 3,6,10,12,12A PENTAHYDROXY 6 METHYL 1,1 DIOXO N (1 PYRROLIDINYLMETHYL) 1,4,4A,5,5A,6,11,12A OCTAHYDRO 2 NAPHTHACENECARBOXAMIDE; 4,5,6,7 TETRACHLORO 3,3 BIS[6 HYDROXY(1,1' BIPHENYL) 3 YL] 3 BENZOFURAN 1(3H)ONE; 4,9 EPOXYCEVANE 3,4,12,14,16,17,20 HEPTOL 3 (3,4 DIMETHOXYBENZOTE); 5' BENZYL 12' HYDROXY 2'METHYL 3,6',18 TRIOXOERGOTAMAN; 6 (2 METHYL 2H INDOL 3 YL] 6' (2' METHYL 3AH INDOL 3YL) 4,4' BIPYRIMIDINE 2,2' DIAMINE; 6,6' DI(NAPHTHALEN 2 YL) 4,4' BIPYRIMIDINE 2,2' DIAMINE; ADENYLATE CYCLASE INHIBITOR; CATECHOL ESTROGEN; FORSKOLIN; N,N BIS(2 BROMOPROPYL) 9H FLUOREN 2 AMINE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; CALCULATION; CELL STRAIN HEK293; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CYANOBACTERIUM; DRUG BINDING; DRUG POTENCY; DRUG SPECIFICITY; DRUG STRUCTURE; EMBRYO; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; MOLECULAR DOCKING;

ADENYLATE CYCLASE; ANIMALS; CELL LINE; CHELATING AGENTS; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 49449098340     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800481q     Document Type: Article

References (39)

1. Hanoune, J.; Defer, N. Regulation and role of adenylyl cyclase isoforms. Annu. Rev. Pharmacol. Toxicol. 2001, 41, 145-174.
2. Kamenetsky, M.; Middelhaufe, S.; Bank, E. M.; Levin, L. R.; Buck, J.; et al. Molecular details of cAMP generation in mammalian cells: a tale of two systems. J. Mol. Biol. 2006, 362, 623-639.
3. Linder, J. U.; Schultz, J. E. The class III adenylyl cyclases: multipurpose signalling modules. Cell Signalling 2003, 15, 1081-1089.
4. Buck, J.; Sinclair, M. L.; Schapal, L.; Cann, M. J.; Levin, L. R. Cytosolic adenylyl cyclase defines a unique signaling molecule in mammals. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 79-84.
5. Jaiswal, B. S.; Conti, M. Identification and functional analysis of splice variants of the germ cell soluble adenylyl cyclase. J. Biol. Chem. 2001, 276, 31698-31708.
6. Chen, Y.; Cann, M. J.; Litvin, T. N.; Iourgenko, V.; Sinclair, M. L.; et al. Soluble adenylyl cyclase as an evolutionarily conserved bicarbonate sensor. Science 2000, 289, 625-628.
7. Litvin, T. N.; Kamenetsky, M.; Zarifyan, A.; Buck, J.; Levin, L. R. Kinetic properties of "soluble" adenylyl cyclase. Synergism between calcium and bicarbonate. J. Biol. Chem. 2003, 278, 15922-15926.
8. Zippin, J. H.; Levin, L. R.; Buck, J. CO(2)/HCO(3)(-)-responsive soluble adenylyl cyclase as a putative metabolic sensor. Trends Endocrinol. Metab. 2001, 12, 366-370.
9. Tesmer, J. J.; Sunahara, R. K.; Gilman, A. G.; Sprang, S. R. Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gsalpha.GTPgammaS. Science 1997, 278, 1907-1916.
10. Steegborn, C.; Litvin, T. N.; Levin, L. R.; Buck, J.; Wu, H. Bicarbonate activation of adenylyl cyclase via promotion of catalytic active site closure and metal recruitment. Nat. Struct. Mol. Biol. 2005, 12, 32-37.
11. Tesmer, J. J.; Sunahara, R. K.; Johnson, R. A.; Gosselin, G.; Gilman, A. G.; et al. Two-metal ion catalysis in adenylyl cyclase. Science 1999, 285, 756-760.
12. Menniti, F. S.; Faraci, W. S.; Schmidt, C. J. Phosphodiesterases in the CNS: targets for drug development. Nat. Rev. Drug Discovery 2006, 5, 660-670.
13. Ishikawa, Y. Isoform-targeted regulation of cardiac adenylyl cyclase. J. Cardiovasc. Pharmacol. 2003, 41 (Suppl. 1), S1-4.
14. Iwatsubo, K.; Okumura, S.; Ishikawa, Y. Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling. Endocr. Metab. Immune Disord. Drug Targets 2006, 6, 239-247.
15. Sinclair, M. L.; Wang, X. Y.; Mattia, M.; Conti, M.; Buck, J.; et al. Specific expression of soluble adenylyl cyclase in male germ cells. Mol. Reprod. Dev. 2000, 56, 6-11.
16. Geng, W.; Wang, Z.; Zhang, J.; Reed, B. Y.; Pak, C. Y.; et al. Cloning and characterization of the human soluble adenylyl cyclase. Am. J. Physiol. Cell Physiol. 2005, 288, C1305-1316.
17. Tesmer, J. J.; Dessauer, C. W.; Sunahara, R. K.; Murray, L. D.; Johnson, R. A.; et al. Molecular basis for P-site inhibition of adenylyl cyclase. Biochemistry 2000, 39, 14464-14471.
18. Dessauer, C. W.; Tesmer, J. J.; Sprang, S. R.; Gilman, A. G. The interactions of adenylate cvclases with P-site inhibitors. Trends Pharmacol. Sci. 1999, 20, 205-210.
19. Gille, A.; Lushington, G. H.; Mou, T. C.; Doughty, M. B.; Johnson, R. A.; et al. Differential inhibition of adenylyl cyclase isoforms and soluble guanylyl cyclase by purine and pyrimidine nucleotides. J. Biol. Chem. 2004, 279, 19955-19969.
20. Levy, D. E.; Bao, M.; Cherbavaz, D. B.; Tomlinson, J. E.; Sedlock, D. M.; et al. Metal coordination-based inhibitors of adenylyl cyclase: novel potent P-site antagonists. J. Med. Chem. 2003, 46, 2177-2186.
21. Iwatsubo, K.; Minamisawa, S.; Tsunematsu, T.; Nakagome, M.; Toya, Y.; et al. Direct inhibition of type 5 adenylyl cyclase prevents myocardial apoptosis without functional deterioration. J. Biol. Chem. 2004, 279, 40938-40945.
22. Shoshani, I.; Laux, W. H.; Perigaud, C.; Gosselin, G.; Johnson, R. A. Inhibition of adenylyl cyclase by acyclic nucleoside phosphorate antiviral agents. J. Biol. Chem. 1999, 274, 34742-34744.
23. Hess, K. C.; Jones, B. H.; Marquez, B.; Chen, Y.; Ord, T. S.; et al. The "soluble" adenylyl cyclase in sperm mediates multiple signaling events required for fertilization. Dev. Cell 2005, 9, 249-259.
24. Mou, T. C.; Gille, A.; Fancy, D. A.; Seifert, R.; Sprang, S. R. Structural basis for the inhibition of mammalian membrane adenylyl cyclase by 2′(3′)-O-(N-Methylanthraniloyl)-guanosine 5′-triphosphate. J. Biol. Chem. 2005, 280, 7253-7261.
25. Steegborn, C.; Litvin, T. N.; Hess, K. C.; Capper, A. B.; Taussig, R.; et al. A novel mechanism for adenylyl cyclase inhibition from the crystal structure of its complex with catechol estrogen. J. Biol. Chem. 2005, 280, 31754-31759.
26. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; et al. Automated Docking Using a Lamarckian Genetic Algorithm and and Empirical Binding Free Energy Function. J. Comput. Chem. 1998, 19, 1639-1662.
27. Li, C.; Xu, L.; Wolan, D. W.; Wilson, I. A.; Olson, A. J. Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identify novel nonfolate inhibitors. J. Med. Chem. 2004, 47, 6681-6690.
28. McInnes, C. Virtual screening strategies in drug discovery. Curr. Opin. Chem. Biol. 2007, 11, 494-502.
29. Pastor-Soler, N.; Beaulieu, V.; Litvin, T. N.; Da Silva, N.; Chen, Y.; et al. Bicarbonate-regulated adenylyl cyclase (sAC) is a sensor that regulates pH-dependent V-ATPase recycling. J. Biol. Chem. 2003, 278, 49523-49529.
30. Sunahara, R. K.; Taussig, R. Isoforms of mammalian adenylyl cyclase: multiplicities of signaling. Mol. Interv. 2002, 2, 168-184.
31. Braun, T. Inhibition of the soluble form of testis adenylate cyclase by catechol estrogens and other catechols. Proc. Soc. Exp. Biol. Med. 1990, 194, 58-63.
32. Esnouf, R.; Ren, J.; Ross, C.; Jones, Y.; Stammers, D.; et al. Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat. Struct. Biol. 1995, 2, 303-308.
33. Jaleel, M.; Shenoy, A. R.; Visweswariah, S. S. Tyrphostins are inhibitors of guanylyl and adenylyl cyclases. Biochemistry 2004, 43, 8247-8255.
34. Ebina, T.; Toya, Y.; Oka, N.; Schwencke, C.; Kawabe, J.; et al. Isoform-specific regulation of adenylyl cyclase by oxidized catecholamines. J. Mol. Cell. Cardiol. 1997, 29, 1247-1254.
35. Remmers, A. E.; Posner, R.; Neubig, R. R. Fluorescent guanine nucleotide analogs and G protein activation. J. Biol. Chem. 1994, 269, 13771-13778.
36. Hutchinson, J. P.; Eccleston, J. F. Mechanism of nucleotide release from Rho by the GDP dissociation stimulator protein. Biochemistry 2000, 39, 11348-11359.
37. Pisareva, V. P.; Pisarev, A. V.; Hellen, C. U.; Rodnina, M. V.; Pestova, T. V. Kinetic analysis of interaction of eukaryotic release factor 3 with guanine nucleotides. J. Biol. Chem. 2006, 281, 40224-40235.
38. Pinto, C.; Papa, D.; Hubner, M.; Mou, T. C.; Lushington, G. H.; et al. Activation and inhibition of adenylyl cyclase isoforms by forskolin analogs. J. Pharmacol. Exp. Ther. 2008, 325, 27-36.
39. DeLano, W. The PyMol User's Manual; DeLano Scientific: San Carlos, CA, 2002.